-
Bayer’s Asundexian Demonstrated a Substantial 26% Reduction in Stroke After a Non-Cardioembolic Ischemic Stroke or High-Risk Transient Ischemic Attack, With No Increase in ISTH Major Bleeding Versus Placebo
Bayer today presented the results from the global, pivotal Phase III OCEANIC-STROKE study evaluating the use of its investigational, once-daily, oral, Factor…
Lifestyle Content
Technology
Health
-
Camfil USA Releases Educational Video Series Addressing Hidden Obstacles to Better School Air Quality
-
Winter Training Made Easy at Semiahmoo Fitness World
-
CCHR: Taxpayer Billions Wasted on Mental Health Research as Outcomes Deteriorate
-
Evolve Vancouver Brings Their Signature “Movement-First” Therapy to New Burnaby Location
